Tags: Drug.
Insulin glulisine is a rapid-acting insulin analogue that differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid. It was developed by Sanofi-Aventis and sold under the trade name Apidra. When injected subcutaneously it appears in the blood earlier than human insulin. When used as a meal time insulin the dose is given within 15 minutes before a meal or within 20 minutes after starting a meal.